| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |